Efficacy and safety of sacituzumab govitecan in hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis
{{output}}
BackgroundSacituzumab govitecan (SG) has shown clinical activity in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer (HR+/HER2- MBC), although evidence remains limited and heterogeneous. We performed a system... ...
